Who are 3,4-diaminopyridine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SR-fampridine, Ezogabine/Retigabine IR, Sustained-release oral dalfampridine, BIIB041 (fampridine), BIIB041 (Fampridine-SR), Retigabine IR.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/3-4-diaminopyridine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

3,4-diaminopyridine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

3,4-diaminopyridine (3,4-diaminopyridine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Potassium channel blocker. Area: Neurology.

phase 3 Potassium channel blocker Voltage-gated potassium channels Neurology Small molecule Live · refreshed every 30 min

Target snapshot

3,4-diaminopyridine (3,4-diaminopyridine) — Oregon Health and Science University. 3,4-diaminopyridine blocks potassium channels to prolong action potential duration and increase acetylcholine release at the neuromuscular junction.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
3,4-diaminopyridine TARGET	3,4-diaminopyridine	Oregon Health and Science University	phase 3	Potassium channel blocker	Voltage-gated potassium channels
SR-fampridine	SR-fampridine	University of Southern Denmark	marketed	Potassium channel blocker	Voltage-gated potassium channels
Ezogabine/Retigabine IR	Ezogabine/Retigabine IR	GlaxoSmithKline	marketed	Potassium channel opener	Kv7 (KCNQ) voltage-gated potassium channels
Sustained-release oral dalfampridine	Sustained-release oral dalfampridine	Sheba Medical Center	marketed	Potassium channel blocker	Voltage-gated potassium channels (Kv channels)
BIIB041 (fampridine)	BIIB041 (fampridine)	Biogen	phase 3	Potassium channel blocker	Voltage-gated potassium channels (Kv)
BIIB041 (Fampridine-SR)	BIIB041 (Fampridine-SR)	Biogen	phase 3	Potassium channel blocker	Voltage-gated potassium channels (Kv1.4, Kv3.1)
Retigabine IR	Retigabine IR	GlaxoSmithKline	phase 3	Potassium channel opener; anticonvulsant	Kv7 (KCNQ) voltage-gated potassium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Potassium channel blocker class)

Orphalan · 3 drugs in this class
Biogen · 2 drugs in this class
Essentialis, Inc. · 1 drug in this class
National Center for Research Resources (NCRR) · 1 drug in this class
Oregon Health and Science University · 1 drug in this class
Sheba Medical Center · 1 drug in this class
University of Southern Denmark · 1 drug in this class
D'Youville College · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 3,4-diaminopyridine — Competitive Intelligence Brief. https://druglandscape.com/ci/3-4-diaminopyridine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing